What is AbbVie's cash & equivalents?

AbbVie (ABBV) reported cash & equivalents of $9.39B in Q1 2026.

How has AbbVie's cash & equivalents changed year-over-year?

AbbVie's cash & equivalents increased by 81.5% year-over-year, from $5.18B to $9.39B.

What is the long-term trend for AbbVie's cash & equivalents?

Over 5 years (2020 to 2025), AbbVie's cash & equivalents has grown at a -9.2% compound annual growth rate (CAGR), from $8.45B to $5.23B.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

AbbVie ABBV Cash & Equivalents

Cash & Equivalents at other companies

Eli LillyLLY

$5.28B+70.8%

PfizerPFE

$1.76B+18.8%

Johnson & JohnsonJNJ

$20.42B+9.9%

AmgenAMGN

$559M+10.0%

Cardinal HealthCAH

$3.94B+18.4%

Vertex PharmaceuticalsVRTX

$5.5B+17.5%

Other financials

Income statement

See full

Revenue$15.0B+12.4%

Gross profit$10.8B+15.4%

Operating income$4.0B+6.9%

Net income$695.0M-46.0%

EPS (diluted)$0.39-45.8%

Balance sheet

See full

Total debt$62.4B+1.8%

Total equity-$6.7B-569%

Total assets$136.46B+0.2%

Cash flow

See full

Operating cash flow$3.8B+134%

CapEx$265.0M+12.8%

Free cash flow$3.6B+155%

Valuation

See full

Market cap$458.24B+37.6%

P/E126.1×+37.6×

P/S7.3×+1.6×

Profitability

See full

Gross margin70.7%0.0pp

Operating margin24.4%—

Net margin5.8%-1.5pp

FCF margin31.8%+5.0pp

Returns & leverage

See full

Return on equity89%+32.7pp

Debt / equity46.6×+38.6×

Current ratio0.8×0.0×

Where this comes from

Reported directly by AbbVie in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: AbbVie’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbbVie's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is AbbVie's cash & equivalents?: AbbVie (ABBV) reported cash & equivalents of $9.39B in Q1 2026.
How has AbbVie's cash & equivalents changed year-over-year?: AbbVie's cash & equivalents increased by 81.5% year-over-year, from $5.18B to $9.39B.
What is the long-term trend for AbbVie's cash & equivalents?: Over 5 years (2020 to 2025), AbbVie's cash & equivalents has grown at a -9.2% compound annual growth rate (CAGR), from $8.45B to $5.23B.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.